Endothelins and coronary vascular biology

Coronary Artery Disease

Volumn 14, Issue 7, 2003, Pages 491-494

  Noori, Arshia ^a   Kabbani, Samer ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Endothelial dysfunction; Endothelin; Restenosis

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ISOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; RESTENOSIS; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATATION;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ARTERIOSCLEROSIS; CORONARY RESTENOSIS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTOR, ENDOTHELIN A; SYNDROME; TUNICA INTIMA;

EID: 0347762597     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200311000-00003     Document Type: Review

References (49)

1. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86:2863-2867.
2. Saida K, Mitsui Y, Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family: molecular cloning, expression, and biological activity. J Biol Chem 1989; 264:14613-14616. This is a landmark paper documenting the discovery of the fourth peptide in the endothelin family as well as its biological activity.
3. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267:16066-16068.
4. Sirous ZN, Fleming JB, Khalil RA. Endothelin-1 enhances eicosanoids-induced coronary smooth muscle contraction by activating specific protein kinase C isoforms. Hypertension 2001; 37:497-504. These authors demonstrated the protein kinase C mediated activity of endothelins in smooth muscle contraction in coronaries.
5. 2+](i) sensitization pathways. Hypertension 2002; 39:543-549.
6. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415. This is the landmark article where endothelins were discovered and found to be the most potent vasoconstrictor peptides.
7. Alberts GF, Peifley KA, Johns A, Klena JF, Winkles TA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269:10112-10118.
8. Dashwood MR, Timm M, Muddle JR, Ong AC, Tippins JR, Parker R, et al. Regional variations in endothelin-1 and its receptor subtypes in human coronary vasculature: pathophysiological implications in coronary disease. Endothelium 1998; 6:61-70.
9. Zouridakis EG, Schwartzman R, Garcia-Moll X, Cox ID, Fredericks S, Holt DW, et al. Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J 2001; 22:1578-1584.
10. Hasdai D, Holmes DR, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997; 2195:357-362.
11. Donatelli M, Hoffmann E, Colletti I, Andolima G, Russo V, Bucalo ML, et al. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 1996; 33:246-248.
12. Ravalli S, Szabolcs M, Albala A, Michler RE, Cannon PJ. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation 1996; 194:2096-2102.
13. Yamaguchi A, Miniati DN, Hirata K, Hoyt EG, Robbins RC. Ex vivo blockade of endothelin-1 inhibits graft coronary artery disease in rodent cardiac allograft model. J Heart Lung Transplant 2002; 21:417-424.
14. Li JJ, Huang CX, Fang CH, Chen F, Jiang H, Tang QZ, et al. Circadian variation in ischemic threshold in patients with stable angina: relation to plasma endothelin-1. Angiology 2002; 53:409-413.
15. Halcox JP, Nour KRA, Zalos G, Quyyumi AA. Coronary vasodilation and Improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 2001; 89:969-976.
16. Kinlay S, Behrendt D, Wainstein W, Betrame J, Fang JC, Creager MA, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104:1114-1118. These authors demonstrated how the activity of endothelins is more pronounced in diseased vessels as compared to normal arteries.
17. Suzuki H, Takeyama Y, Matsubara H, Hasegawa S, Hiroshige J, Murakami M, et al. Plasma endothelin-1 and thrombomodulin levels in coronary sinus during right atrial pacing and percutaneous transluminal coronary angioplasty. Intl J Cardiol 2000; 74:15-23.
18. Kruger D, Giannitsis E, Sheikhzadeh A, Stierle U. Cardiac release and kinetics of endothelin after uncomplicated percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 81:1421-1426.
19. Kyriakides ZS, Kremastinos DT, Bofilis E, Tousoulis D, Antoniadis A, Webb DJ. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary angiography. Heart 2000; 84:176-182.
20. Brehm BR, Buttcher E, Beyer ME, Hoffmeister HM. Comparison of circulating endothelin-1 and big endothelin-1 levels in unstable versus stable angina pectoris. J Cardiovasc Pharmacol 1998; 31 (suppl 1):S90-S93.
21. Vojacek J, Kolá J, Lisý O, Hrabos V, Imek S, Jindra A, Jachymova M. Time course of endothelin-1 plasma level in patients with acute coronary syndrome. Cardiology 1999; 91:114-118.
22. Battistelli S, Billi M, Manasse G, Vittoria A, Roviello F, Forcini S. Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction. Angiology 1999; 50:629-638.
23. Gonon AT, Wang QD, Shimizu M, Pernow J. The novel non-peptide selective endothelin A receptor antagonist LU 135,252 protects against myocardial ischaemic and reperfusion injury in the pig. Acta Physiol Scand 1998; 163:131-137.
24. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27:1613-1618.
25. Gourine AV, Gonon AT, Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol (Heart Circ Physiol) 2001; 280: H1105-H1112. These authors demonstrated the activity balance between endothelins and nitric oxide in endothelial cells and the protective effects of nitric oxide in ischemic-reperfusion injury.
26. Martin P, Tzanidis A, Stein-Oakley A, Krum H. Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rates after myocardial infarction. J Cardiovasc Pharmacol 2000; 36 (suppl 1): S367-S370.
27. Oie E, Yndestad A, Robins SP, Bjornerheim R, Asberg A, Attramadal H. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Bas Res Cardiol 2002; 97:239-247.
28. Nguyen QT, Cernacek P, Sirois MG, Calderone A, Lapointe N, Stewart DJ, Rouleau JL. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001; 104:2075-2081.
29. Takahashi C, Kagaya Y, Namiuchi S, Takeda M, Fukachi M, Otani H, et al. Nonselective endothelin antagonist initiated soon after the onset of myocardial infarction may deteriorate 24-hour survival. J Cardiovasc Pharmacol 2001; 38:29-38.
30. Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci USA 1999; 96:6920-6924.
31. Douglas SA, Ohlstein EH. Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J Cardiovasc Pharmacol 1993; 22 (suppl 8): S371-S373.
32. Igase M, Okura T, Kitami Y, Hiwada K. Apoptosis and Bcl-xs in the intimal thickening of balloon-injured carotid arteries. Clin Sci 1999; 96:605-612.
33. Barolet AW, Babaei S, Robinson R, Picard P, Winston T, Nili N, et al. Administration of exogenous endothelin-1 following vascular balloon injury: early and late effects on intimai hyperplasia. Cardiovasc Res 2001; 52: 468-476.
34. Rizvi MAD, Katwa L, Spadone DP, Myers PR. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 1996; 28:243-252.
35. Katwa LC, Campbell SE, Tanner MA, Myers PR. The upregulation of endothelin and its receptors in porcine coronary arteries in a double balloon injury model for restenosis. Bas Res Cardiol 1999; 94:445-453.
36. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ, Ohlstein EH. Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 1996; 78:322-328.
37. Buchwald AB, Wagner AH, Webel C, Hecker M. Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. J Am Coll Cardiol 2002; 39:732-738.
38. Ferrer P, Valentine M, Jenkins-West T, Weber H, Goller NL, Durham SK, et al. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J Cardiovasc Pharmacol 1995; 26:908-915.
39. Burke SE, Lubbers NL, Gagne GD, Wessale JL, Dayton BD, Wegner CD, Opgenorth TJ. Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. J Cardiovasc Pharmacol 1997; 30:33-41.
40. McKenna CJ, Burke SE, Opgenorth TJ, Padley RJ, Camrud LJ, Camrud AR, et al. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 1998; 97:2551-2556.
41. Dashwood MR, Noertersheuser P, Kirchengast M, Munter K. Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: effect of the ETA receptor antagonist, LU 135252. Cardiovasc Res 1999; 43:445-456.
42. Tsujino M, Hirata Y, Eguchi S, Watanabe T, Chatani F, Marumo F. Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci 1995; 56:PL449-PL454.
43. Azuma H, Sato J, Masuda H, Goto M, Tamaoki S, Sugimoto A, et al. ATZ 1993, an orally active and novel nonpeptide antagonist for endothelin receptors and inhibition of intimal hyperplasia after balloon denudation of the rabbit carotid artery. Jpn J Pharmacol 1999; 81:21-28.
44. Kirchengast M. Endothelin receptor blockade and in-stent restenosis. J Cardiovasc Pharmacol 2001; 38 (suppl 2):S31-S34.
45. Huckle WR, Drag MD, Acker WR, Powers M, McFall RC, Holder DJ, et al. Effects of L-749,329, an ET(A)/ET(B) endothelin receptor antagonist, in a procine coronary artery injury model of vascular restenosis. Circulation 2001; 103:1899-1905.
46. Pham D, Jeng AY, Plante S, Escher E, Battistini B. Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Can J Physiol Pharmacol 2002; 80:450-457.
47. Nakahashi T, Fukuo K, Nishimaki H, Hata S, Shimizu M, Suhara T, et al. Endothelin-1 enhances nitric oxide-induced cell death in cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol 1998; 31 (suppl 1): S351-S353. This article examined the aspects of apoptosis in endothelial cells. The authors were able to demonstrate that the programmed cell death of vascular smooth muscles is induced by nitric oxide.
48. Cattaruzza M, Berger MM, Ochs M, Fayyazi A, Fuzesi L, Richter J, Hecker M. Deformation-induced endothelin B receptor-mediated smooth muscle cell apoptosis is matrix-dependent. Cell Death Diff 2002; 9: 219-226.
49. Porter KE, Olojugba DH, Masood I, Pemberton M, Bell PRF, London NJM. Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 1998; 28:695-701.